Polymyalgia rheumatica (RP) is a systemic inflammatory disease characterized by severe pain and stiffness in the shoulder and pelvic girdle. It usually occurs in people over 50 years of age, especially in women, and is autoimmune in nature. RP is associated with high levels of inflammatory markers, such as C-reactive protein and erythrocyte sedimentation rate. Sleep and functional activity of patients are often impaired due to severe muscle weakness and discomfort. Although the disease has a relatively good prognosis with adequate therapy, lack of diagnosis and treatment can lead to a significant deterioration in quality of life.
History of the disease and interesting historical facts
Polymyalgia rheumatica was first described in medical literature in the mid-20th century. One of the key moments in the history of the disease was its differentiation from other rheumatic diseases, such as inflammatory arthritis. In 1957, Johnson and Brown described a clinical picture caused by muscle pain in the elderly. Since then, the study of RP has become more systematic and scientifically substantiated. Scientists have identified a link between RP and other diseases, such as giant cell arteritis, which has become a significant step in understanding the pathogenesis of these conditions. An interesting fact is that in some cases, RP can precede the development of such serious diseases as arteritis.
Epidemiology
Epidemiological studies show that polymyalgia rheumatica is a common disease among the elderly. Statistics indicate an incidence of about 50 cases per 100,000 people per year, making RP one of the most common rheumatic diseases in the elderly. In particular, women suffer from RP 2-3 times more often than men, and most often symptoms occur after 50 years. Some studies have indicated that the incidence can reach 60 cases per 100,000 among people over 65 years of age. There is also evidence of racial predisposition, where the disease is more common among Scandinavian peoples compared to African and Asian populations.
Genetic predisposition to this disease
Genetic predisposition plays an important role in the development of polymyalgia rheumatica. Genetic studies have revealed associations between RP and certain alleles of the major histocompatibility complex (HLA). Specifically, the HLA-DR4 and HLA-DR1 alleles have shown an increased risk of developing the disease. Some studies also indicate a link with mutations in genes responsible for the immune response. It is important to note that the presence of predisposing genes does not necessarily mean the development of RP, since the disease is the result of the interaction of genetic and external factors.
Risk factors for the development of this disease
Various factors can increase the risk of developing polymyalgia rheumatica. The main ones include:
- Age: More common in people over 50 years of age.
- Gender: Women are affected more often than men.
- Genetic predisposition: Having a family history of RP increases the risk.
- Infectious processes: some viral infections can provoke the manifestation of the disease.
- Environmental factors: Exposure to certain chemicals and toxins is also considered a potential trigger.
It is important to understand that the presence of one or more risk factors does not guarantee the development of the disease, but it increases the likelihood of its occurrence.
Diagnosis of this disease
Diagnosis of polymyalgia rheumatica requires a comprehensive approach and includes the following aspects:
- The main symptoms are characteristic pain and stiffness in the shoulders and hips, as well as general malaise and weight loss.
- Laboratory tests: determination of the level of inflammatory markers (C-reactive protein, erythrocyte sedimentation rate).
- Radiological examinations: X-rays may be used to rule out other joint diseases.
- Other diagnostic tests: Ultrasound can help assess inflammatory changes in soft tissues.
- Differential diagnosis: Other diseases such as rheumatoid arthritis, osteoarthritis and thyroid disease must be excluded.
All these methods allow the doctor to more accurately diagnose RP and begin the correct treatment.
Treatment
Treatment of polymyalgia rheumatica is based on a comprehensive approach and includes both pharmacological and non-pharmacological interventions:
- General treatment: It is important to provide the patient with rest and exercise to maintain muscle function.
- Pharmacological treatment: Non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are the mainstay of therapy.
- Surgical treatment: In rare cases, surgery may be required to correct complications.
- Other treatments: Physical therapy and exercise therapy can help improve patients' quality of life.
Complex treatment provides control over symptoms and reduces the activity of the inflammatory process.
List of medications used to treat this disease
There are several groups of drugs that are used in the treatment of RP:
- Nonsteroidal anti-inflammatory drugs (NSAIDs): ibuprofen, diclofenac.
- Corticosteroids: prednisolone, methylprednisolone.
- Immunosuppressants: methotrexate, azathioprine.
- Biological drugs: tocilizumab, abatacept (in cases of resistance to traditional treatment).
These medications help control symptoms and reduce inflammation.
Disease monitoring
Monitoring of the condition of patients with polymyalgia rheumatica includes:
- Regular medical examinations to assess the clinical condition and dynamics of the disease.
- Laboratory tests to monitor levels of inflammatory markers.
- Prevention of possible complications such as osteoporosis and related diseases.
- Assessing quality of life and adapting treatment according to the patient's condition.
The prognosis with adequate therapy is generally favorable, but careful monitoring is necessary.
Age-related features of the disease
Polymyalgia rheumatica manifests itself differently depending on the patient's age:
- In people over 50 years of age, the disease often occurs in more severe forms with pronounced symptoms.
- People aged 70 years and older are more likely to develop concomitant diseases.
- In young patients (under 50 years), RP is extremely rare, and if symptoms occur, special attention is required to exclude other pathogenesis.
Each age-related aspect requires an individualized approach to diagnosis and treatment.
Questions and Answers
- What are the main symptoms of polymyalgia rheumatica?
The main symptoms are pain and stiffness in the shoulders and hips, general malaise and weight loss. - How is polymyalgia rheumatica diagnosed?
Diagnosis includes clinical symptoms, laboratory tests (levels of inflammatory markers) and radiological examinations to exclude other diseases. - Who is more likely to get polymyalgia rheumatica?
Most often, the disease occurs in women over 50 years of age. - What treatment is recommended for polymyalgia rheumatica?
Treatment includes nonsteroidal anti-inflammatory drugs, corticosteroids, and exercise to maintain activity. - What is the prognosis for polymyalgia rheumatica?
The prognosis is generally favorable with adequate therapy and regular monitoring of the condition.
